rAAV.hCNGA3

DRUG2 trials

Sponsors

Universitaetsklinikum Tuebingen AöR, STZ eyetrial

Conditions

AchromatopsiaCNGA3-linked achromatopsia

Phase 1

Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia

Active, not recruitingNCT02610582

STZ eyetrialAchromatopsia

Start: 2015-11-30End: 2027-06-30Updated: 2024-04-18

Safety and efficacy of a bilateral single subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia investigated in a randomized, wait list controlled, observer-masked trial (Colour Bridge)

Active, not recruitingCTIS2024-515553-17-00

Universitaetsklinikum Tuebingen AöRCNGA3-linked achromatopsia

Start: 2021-03-11Target: 14Updated: 2025-03-06

Related Papers

Three-year results of phase I retinal gene therapy trial for CNGA3-mutated achromatopsia: results of a non randomised controlled trial

British Journal of Ophthalmology2021-05-1870 citations

Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia

JAMA Ophthalmology2020-04-30172 citations

Humoral Immune Response After Intravitreal But Not After Subretinal AAV8 in Primates and Patients.

2018-04-0171 citations

Residual Foveal Cone Structure in <i>CNGB3</i>-Associated Achromatopsia

Investigative Ophthalmology & Visual Science2016-08-01108 citations